Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Marie Skłodowska-Curie Action · Running

PDT-NEO-immunother Generation of tumor neoantigens with photodynamic therapy: a new strategy for anticancer vaccines to fight head and neck cancer

Coordinator
Universiteit Gent, Belgium
Runs
1 December 2023 to 30 November 2025
Status
Running
EU funding
€176k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101108930

What the project is doing

In the project's own words, from its summary on CORDIS.

Immunogenic cell death (ICD) is a regulated cell death that stimulates the immune responses resulting in the establishment of long- term immunological memory. ICD alert the immune system by tumor-associated antigens and tumor neoantigens (i.e., antigenicity) and releasing immunostimulant mediators such as the damage- associated molecular patterns (DAMPs, adjuvanticity). ICD can be efficiently induced by photodynamic therapy (PDT).

Our key hypothesis is that PDT based on clinically approved and in-house developed photosensitizers, which are efficient in several murine cancer models, will induce ICD in head and neck squamous cell carcinomas (HNSCCs) which are the fourth most frequent types of cancer in men. Specifically, we aim to demonstrate for the first time that PDT will modulate the immunogenicity of dying HNSCC cells not only by releasing DAMPs but also by increasing antigenicity of dying HNSCC cells by affecting their landscape of antigens.

This will lead to the activation of the innate and adaptive immune system and to the improvement of anti-cancer therapy of HNSCC patients. For the study, we will exploit HNSCC cells derived from patients’ biopsies, representing an ideal preclinical model that incorporates heterogeneity of tumors observed in patients. In this way, we will obtain the data required to support future clinical trials based on PDT. Indeed, the ultimate goal of the neoantigen identification is to pave the way for developing patient-specific targeted vaccine therapies.

Topics

Who is involved

OrganisationCityCountryRole
Universiteit GentGentBelgiumCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI